Uveal Melanoma-Pipeline Review, H1 2017

Uveal Melanoma-Pipeline Review, H1 2017


  • Products Id :- GMDHC9207IDB
  • |
  • Pages: 129
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Uveal Melanoma-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma-Pipeline Review, H1 2017, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 9, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Uveal Melanoma-Overview

Uveal Melanoma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uveal Melanoma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uveal Melanoma-Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Cleveland BioLabs Inc

Delcath Systems Inc

Eli Lilly and Company

Iconic Therapeutics Inc

Immunocore Ltd

Lion Biotechnologies Inc

Navigen Inc

Novartis AG

PEP-Therapy SAS

Pfizer Inc

Polaris Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Uveal Melanoma-Drug Profiles

AU-011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Metastatic Uveal Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entolimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glembatumumab vedotin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hI-con1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-211-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCgp-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCN-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXS-196-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-2729-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nutlin-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegargiminase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEP-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotrastaurin acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vincristine sulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uveal Melanoma-Dormant Projects

Uveal Melanoma-Discontinued Products

Uveal Melanoma-Product Development Milestones

Featured News & Press Releases

Nov 09, 2016: Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016

Mar 30, 2016: Immunocore's IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma

Jan 25, 2016: Immunocore's IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC

Sep 09, 2015: Immunocore's IMCgp100 Accepted for Adaptive Pathway Pilot Programme

Jun 29, 2015: Lilly and Immunocore To Conduct Phase Ib/II Clinical Trial Collaboration For Treatment Of uveal melanoma

May 22, 2015: Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results

May 21, 2015: FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma

Apr 14, 2015: Navigen Announces Phase I SBIR Award to Support Development of Uveal Melanoma Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Uveal Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Uveal Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Uveal Melanoma-Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Uveal Melanoma-Pipeline by Bristol-Myers Squibb Company, H1 2017

Uveal Melanoma-Pipeline by Celldex Therapeutics Inc, H1 2017

Uveal Melanoma-Pipeline by Cleveland BioLabs Inc, H1 2017

Uveal Melanoma-Pipeline by Delcath Systems Inc, H1 2017

Uveal Melanoma-Pipeline by Eli Lilly and Company, H1 2017

Uveal Melanoma-Pipeline by Iconic Therapeutics Inc, H1 2017

Uveal Melanoma-Pipeline by Immunocore Ltd, H1 2017

Uveal Melanoma-Pipeline by Lion Biotechnologies Inc, H1 2017

Uveal Melanoma-Pipeline by Navigen Inc, H1 2017

Uveal Melanoma-Pipeline by Novartis AG, H1 2017

Uveal Melanoma-Pipeline by PEP-Therapy SAS, H1 2017

Uveal Melanoma-Pipeline by Pfizer Inc, H1 2017

Uveal Melanoma-Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Uveal Melanoma-Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Uveal Melanoma-Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Uveal Melanoma-Dormant Projects, H1 2017

Uveal Melanoma-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celldex Therapeutics Inc, Cleveland BioLabs Inc, Delcath Systems Inc, Eli Lilly and Company, Iconic Therapeutics Inc, Immunocore Ltd, Lion Biotechnologies Inc, Navigen Inc, Novartis AG, PEP-Therapy SAS, Pfizer Inc, Polaris Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Syndax Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com